Theranostics & You | Riding the pipeline of personalisation in new nuclear medicines

If you’ve been impacted by prostate cancer, the term ‘theranostics’ is probably at the top of your news list. The rapidly emerging treatment modality combines therapy and diagnostics to improve our understanding of each man’s cancer, and how it can be effectively treated, heralding a complete transformation of care.
Impressively, Australia has rapidly established itself as a global pioneer in the field, with clinical trials such as the ProPSMA study and TheraP delivering groundbreaking findings that have helped to establish new standards of care locally and globally.
In this webinar, we bring together experts and survivors to talk about theranostics and you - knowing when to go nuclear, and whether it will work.
This webinar is hosted by Matt Britland, President of the APPA, along with David Cade, Chief Executive Officer of Telix Asia Pacific; Associate Professor Shahneen Sandhu, Consultant Medical Oncologist and Researcher at Peter MacCallum Cancer Centre; and Will McDonald, advanced prostate cancer survivor and PCFA Ambassador.
Call 1800 22 00 99 or go to www.pcfa.org.au/support/prostate-cancer-specialist-nurses/ for information and support.
Proudly sponsored by Telix & MedWise.